Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05706389 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle- Aged Adults?

Study acronym: ABLE
StatusActive, Not Recruiting
PhasePhase 2
Started2023-02-24
View on ClinicalTrials.gov ↗

Amendment history

2026-05-20
notable
Recruiting→Active, Not Recruiting Study Status, Sponsor/Collaborators, Contacts/Locations v3
Trial statusRecruiting→Active, Not Recruiting
Primary completion dateestimated 2024-01-15→confirmed 2025-08-15
Completion date2025-01-15→2027-01-15
Study sitesdetails revised at 1 of 1 site
Collaborators2 entries, revised
AgencyGenome forInstitute Science,of Technology and ResearchSingapore
2023-04-23
minor
Study Status, Study Description, Arms and Interventions v2
Study description-2 characters
[...] , impaired proteostasis, decline in stem cell functions and inflammation45inflammation. These overlapping changes over the lifetime affect the ons [...]
2023-03-20
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-02-20→confirmed 2023-02-24
Study sites0→1
2023-01-20
minor
Original filing
Geroscience is an emerging interdisciplinary field of study in gerontological sciences. With emphasis on understanding the mechanistic drivers of aging, it seeks translational approaches that could eventually be applied to improve human healthspan and delay age-associated chronic diseases. Contrary to popular opinion that aging is irreversible, advances in geroscience research have demonstrated that aging is modifiable and inhibiting or activating specific molecular pathways can improve healthspan and extend lifespan in model organisms. Advocates of geroscience take the view that age-related chronic diseases are best treated by slowing the aging process, rather than using the prevailing disease-centric approach of addressing each disease alone. Thus, the concept is that biological aging, rather than chronological aging, is amenable to intervention. In this regard, geroscientists are at the forefront of longevity medicine in rigorously testing novel supplements, drugs and other prophylactics that can enhance healthspan. Some of these interventions involve repurposing existing drugs such as rapamycin, a well-known immunosuppressant, at different dosing regimens to specifically target biological hallmarks of aging. This study will investigate the effects of alpha-ketoglutarate (AKG), an endogenous metabolite, on biomarkers of aging in middle-aged residents of Singapore.
Trial Details
NCT Number NCT05706389
Lead Sponsor National University of Singapore
Collaborators: AMILI Pte. Ltd., Genome Institute of Singapore
Conditions Aging
Enrollment 120 participants
Start Date 2023-02-24
Primary Completion 2025-08-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-26